ZLAB's Quality Score fell 2 points on Tue, Nov 10, to 3. Buying slipped from its highest in 20 days (3 chart checks stopped).
Follow ZLAB's trial news. Pro members can get an alert when Zai Lab files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 22% from Nov 2 to Nov 10.
“Net product revenue increased 2% versus the second quarter of 2026, primarily driven by NUZYRA, supported by increased market coverage and penetration, and KarXT”
| Holding it back | A $198M loss |
| Latest filing | 8-K, Nov 5 |
Fri Nov 6Zai Lab Q3 Earnings Call Highlights
After its last 4 reports it closed +2.1% on average, higher 2 of 4 times.
About 14 quarters
CFO Yajing Chen sold 260 shares on Aug 19, under a planned sale. 31 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
ZLAB is #41 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 41 |
Share count against a year before: ZLAB +1.9%, XENE +26%, ABCL +6.4%, PTGX +4.1%.
Expected to report Thu Feb 25, before the open (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $108.2M, 7% less than a year ago; a loss of $0.04 a share, from $0.03.
“Net product revenue increased 2% versus the second quarter of 2026, primarily driven by NUZYRA, supported by increased market coverage and penetration, and KarXT, which was launched in June 2026, partially offset by a decrease in OPTUNE due to evolving competition in the glioblastoma market.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Zejula | $32.3M | $32.1M | $42.4M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
No outlook figures read from this release.
“The increase in net loss was primarily due to a $13.6 million in inventory write-downs in 2026.”
From its results filing (SEC filing · Nov 5)
Sales grew 29% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 7.1% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +0.5% | -0.9% | not yet |
| Aug 6, 2026 | +3.7% | +13.7% | +38.8% |
| May 7, 2026 | -2.3% | -5.9% | -2.6% |
| Feb 26, 2026 | -3.0% | +1.6% | -0.6% |
Sales grew every year from 2019 to 2025, to $460M. It lost money in each of the seven years.
RSI 60.8, MACD above signal, above both averages. Not scored.
One insider bought $33K across 1 filing, and 3 insiders sold $670K across 4 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
“Competition in the biopharmaceutical industry is intense.”
ZLAB scores 3 today, which Breakaway calls Below Average. It is #41 of 90 in Pharma by Quality Score, with 4 of 14 chart checks firing. Up 22% from Nov 2 to Nov 10. Cash lasts about 14 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ZLAB scores 3 today, which Breakaway calls Below Average (0 to 5). That is #41 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ZLAB's 3.
One insider bought $33K across 1 filing, and 3 insiders sold $670K across 4 filings, in the last 6 months. The newest is Richard Gaynor, Director, who bought $33K on Jul 1. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.